Novo Nordisk announced Monday that in two closely watched studies, an oral version of semaglutide — the active ingredient in ...

Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of ...

Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit ...

A pill version of A/S’s Ozempic failed to slow the progression of Alzheimer’s disease in a pair of long-shot studies that ...

Shares of Novo Nordisk ( NVO 5.58%) fell on Monday, finishing down 5.6%. The drop comes as the S&P 500 and the Nasdaq ...

A glimmer of hope for Alzheimer’s patients vanished Monday, when Novo Nordisk said a trial of an oral version of its weight ...

Novo Nordisk A/S is rated a Strong Buy with a huge unmet demand in obesity treatment and a low 13x P/E ratio. Learn more ...

Novo Nordisk A/S remains a Strong Buy despite semaglutide's Alzheimer's trial miss. Click for NVO growth drivers, solid ...

Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of blockbuster drugs Ozempic and Wegovy, but scientists are still asking if GLP-1 drugs ...

Novo Nordisk stock falls after disappointing results from Alzheimer's trial. Analysts remain cautious about future growth ...

Yesterday's "bad" news from Novo Nordisk came from its Phase 3 trials of oral semaglutide in the early stage of Alzheimer's ...

On November 24, 2025, Novo Nordisk announced top-line results from its phase 3 evoke and evoke+ trials, revealing that oral semaglutide did not show superiority over placebo in slowing progression of ...